Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.

Pengtao Liu,Zhongbao Zuo,Yiming Shao,Hui Xing,Wei Xu,Jing Wang,Lingjie Liao,Xuebing Leng,Yinghui You,Jing Yan,Wei Kan,Yuhua Ruan

doi:10.1097/md.0000000000013555

Abstract

Stavudine (D4T), zidovudine (AZT), and tenofovir (TDF) along with lamivudine (3TC) are the most widely used HIV treatment regimens in China. China's National Free Antiretroviral Treatment Programme (NFATP) has replaced D4T with AZT or TDF in the standard first-line regimens since 2010. Few studies have evaluated the adherence, virological outcome, and drug resistance in HIV patients receiving first-line antiretroviral therapy (ART) from 2011 to 2015 due to changes in ART regimen.From 2011 to 2015, 2787 HIV patients were examined, with 364, 1453, and 970 patients having initiated D4T-, AZT-, and TDF-based first-line ART regimens, respectively. The Cochran–Armitage test was used to examine the trends in clinical and virological outcomes during 2011 to 2015. Logistic regression was used to examine the effects of different regimens after 9 to 24 months of ART.From 2011 to 2014–2015, adverse drug reactions decreased from 18.9% to 6.7%, missed doses decreased from 9.9% to 4.6%, virological failure decreased from 16.2% to 6.4%, and drug resistance rates also significantly decreased from 5.4% to 1.1%. These successes were strongly associated with the standardized use of TDF- or AZT-based regimens in place of the D4T-based regimen. Poor adherence decreased from 11.3% in patients who initiated D4T-based regimens to 4.9% in those who initiated TDF-based regimens, adverse drug reactions decreased from 32.4% to 6.7%, virological failure reduced from 18.7% to 8.6%, and drug resistance reduced from 5.8% to 2.9%. Compared with patients who initiated AZT-based regimens, patients who initiated TDF-based regiments showed significant reductions in adherence issues, adverse drug reactions, virological outcomes, and drug resistance. Significant differences were also observed between those who initiated D4T- and AZT-based regimens.The good control of HIV replication and drug resistance was attributed to the success of China's NFATP from 2011 to 2015. This study provided real world evidence for further scaling up ART and minimizing the emergence of drug resistance in the “Three 90” era.

Highlights

Stavudine (D4T) and zidovudine (AZT) are not recommended as first-line therapy in well-resourced settings, these thymidine analogues, along with lamivudine (3TC), have formed the most widely used combinations in low- and middle-income countries (LMICs).[1,2] In many of Asia and other resource-limited settings, the most common first-line regimens for HIV-infected patients still contain either D4T or AZT.[1,3,4] But over the last decade, antiretroviral therapy (ART) has gradually improved survival rate and lifeEditor: Ramon Teira Cobo
After adjustment for age, ethnicity, education, sex, marital status, occupation, route of HIV transmission, and CD4 count before ART, patients who initiated TDF-based ART had 62% lower odds of having missed doses in the past month [adjusted OR (AOR), 0.38; 95% CI, 0.24–0.60], 83% lower odds of adverse drug reactions (AOR, 0.17; 95% CI, 0.12–0.24), 56% lower odds of virological failure (AOR, 0.44; 95% CI, 0.30–0.64), and 52% lower odds of HIV drug resistance (HIVDR) (AOR, 0.48; 95% CI, 0.27–0.87)
After adjustment for age, ethnicity, education, sex, marital status, occupation, route of HIV transmission, and CD4 count before ART, patients who initiated TDF-based ART had 32% lower odds of having missed doses in the past month [adjusted OR (AOR), 0.68; 95% CI, 0.48–0.98], 29% lower odds of adverse drug reactions (AOR, 0.71; 95% CI, 0.52–0.97), 30% lower odds of virological failure (AOR, 0.70; 95% CI, 0.52–0.93), and 39% lower odds of HIVDR (AOR, 0.61; 95% CI, 0.38–0.97)

Summary

Introduction

Stavudine (D4T) and zidovudine (AZT) are not recommended as first-line therapy in well-resourced settings, these thymidine analogues, along with lamivudine (3TC), have formed the most widely used combinations in LMICs.[1,2] In many of Asia and other resource-limited settings, the most common first-line regimens for HIV-infected patients still contain either D4T or AZT.[1,3,4] But over the last decade, antiretroviral therapy (ART) has gradually improved survival rate and lifeEditor: Ramon Teira Cobo. Stavudine (D4T) and zidovudine (AZT) are not recommended as first-line therapy in well-resourced settings, these thymidine analogues, along with lamivudine (3TC), have formed the most widely used combinations in LMICs.[1,2] In many of Asia and other resource-limited settings, the most common first-line regimens for HIV-infected patients still contain either D4T or AZT.[1,3,4] But over the last decade, antiretroviral therapy (ART) has gradually improved survival rate and life

Objectives

Results

Conclusion